Neuland Laboratories Limited (NEULANDLAB.NS)
INR 11753.45
(7.24%)
INR 11753.45
(7.24%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.74 Billion INR | 64.28% |
| 2022 | 2.81 Billion INR | 97.55% |
| 2021 | 1.44 Billion INR | -9.27% |
| 2020 | 1.62 Billion INR | 57.16% |
| 2019 | 1.05 Billion INR | 77.74% |
| 2018 | 618.63 Million INR | 14.17% |
| 2017 | 549.66 Million INR | -40.45% |
| 2016 | 1.07 Billion INR | 12.67% |
| 2015 | 822.23 Million INR | 25.8% |
| 2014 | 676.48 Million INR | -16.6% |
| 2013 | 767.25 Million INR | 21.11% |
| 2012 | 659.67 Million INR | 20.55% |
| 2011 | 479.39 Million INR | 0.29% |
| 2010 | 478.01 Million INR | 82.5% |
| 2009 | 261.92 Million INR | -11.45% |
| 2008 | 295.78 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.23 Billion INR | 32.53% |
| 2023 Q2 | 1.4 Billion INR | 42.01% |
| 2023 Q1 | 989.59 Million INR | -22.64% |
| 2023 Q4 | 1.06 Billion INR | -13.33% |
| 2023 FY | - INR | 64.28% |
| 2023 Q3 | 1.23 Billion INR | -12.22% |
| 2022 Q4 | 1.27 Billion INR | 132.52% |
| 2022 Q2 | 695.35 Million INR | 138.82% |
| 2022 FY | - INR | 97.55% |
| 2022 Q1 | 291.16 Million INR | -18.07% |
| 2022 Q3 | 550.16 Million INR | -20.88% |
| 2021 Q1 | 277.44 Million INR | -18.47% |
| 2021 FY | - INR | -9.27% |
| 2021 Q3 | 343.32 Million INR | -20.38% |
| 2021 Q4 | 355.38 Million INR | 3.51% |
| 2021 Q2 | 431.2 Million INR | 55.42% |
| 2020 Q2 | 414.67 Million INR | 20.05% |
| 2020 FY | - INR | 57.16% |
| 2020 Q4 | 340.32 Million INR | -27.27% |
| 2020 Q3 | 467.95 Million INR | 12.85% |
| 2020 Q1 | 345.41 Million INR | 30.48% |
| 2019 Q3 | 291.82 Million INR | 14.36% |
| 2019 FY | - INR | 77.74% |
| 2019 Q4 | 264.73 Million INR | -9.28% |
| 2019 Q2 | 255.18 Million INR | 33.04% |
| 2019 Q1 | 191.81 Million INR | 36.45% |
| 2018 Q3 | 163.65 Million INR | 6.0% |
| 2018 Q2 | 154.39 Million INR | 50.63% |
| 2018 Q1 | 102.49 Million INR | 0.0% |
| 2018 FY | - INR | 14.17% |
| 2018 Q4 | 140.56 Million INR | -14.11% |
| 2017 FY | - INR | -40.45% |
| 2016 Q4 | 369.9 Million INR | 96.04% |
| 2016 Q3 | 188.68 Million INR | -23.07% |
| 2016 Q2 | 245.25 Million INR | 0.96% |
| 2016 FY | - INR | 12.67% |
| 2016 Q1 | 242.92 Million INR | 0.0% |
| 2015 FY | - INR | 25.8% |
| 2014 FY | - INR | -16.6% |
| 2013 FY | - INR | 21.11% |
| 2012 FY | - INR | 20.55% |
| 2011 FY | - INR | 0.29% |
| 2010 FY | - INR | 82.5% |
| 2009 FY | - INR | -11.45% |
| 2008 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 50.626% |
| Hester Biosciences Limited | 539.47 Million INR | -780.157% |
| Aarti Drugs Limited | 3.24 Billion INR | -46.16% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -21.455% |
| Albert David Limited | 1.04 Billion INR | -354.188% |
| Alembic Limited | 1.11 Billion INR | -325.335% |
| Alkem Laboratories Limited | 24.19 Billion INR | 80.375% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -4043.882% |
| Bajaj HealthCare Limited | 406.23 Million INR | -1068.818% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -36435.734% |
| Brooks Laboratories Limited | 41.72 Million INR | -11278.892% |
| Eris Lifesciences Limited | 6.98 Billion INR | 32.037% |
| FDC Limited | 3.38 Billion INR | -40.256% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 30.814% |
| Gufic Biosciences Limited | 1.48 Billion INR | -220.718% |
| Hikal Limited | 2.69 Billion INR | -76.366% |
| Ind-Swift Limited | 1.06 Billion INR | -345.811% |
| Innova Captab Limited | 1.66 Billion INR | -184.61% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -82.16% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -1367.935% |
| Jubilant Pharmova Limited | 8 Billion INR | 40.692% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -253.466% |
| Lupin Limited | 36.96 Billion INR | 87.156% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -2614.085% |
| Medico Remedies Limited | 129.09 Million INR | -3578.083% |
| Morepen Laboratories Limited | 1.72 Billion INR | -175.105% |
| Nectar Lifesciences Limited | 1.53 Billion INR | -209.209% |
| Orchid Pharma Limited | 1.41 Billion INR | -234.573% |
| Procter & Gamble Health Limited | 3.07 Billion INR | -54.443% |
| RPG Life Sciences Limited | 1.28 Billion INR | -270.518% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -1551.973% |
| Sigachi Industries Limited | 883.39 Million INR | -437.491% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 268.262% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -1.518% |
| Themis Medicare Limited | 562.6 Million INR | -743.961% |
| Unichem Laboratories Limited | 742.35 Million INR | -539.61% |
| Vaishali Pharma Limited | 31.71 Million INR | -14873.303% |
| Wanbury Limited | 985.49 Million INR | -381.809% |
| Windlas Biotech Limited | 781.72 Million INR | -507.402% |
| ZIM Laboratories Limited | 462.09 Million INR | -927.53% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 30.801% |
| Ipca Laboratories Limited | 13.29 Billion INR | 64.298% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 96.568% |
| Venus Remedies Limited | 711.8 Million INR | -567.066% |
| Sakar Healthcare Limited | 393.26 Million INR | -1107.366% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 92.315% |
| Divi's Laboratories Limited | 25.43 Billion INR | 81.328% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -101.467% |
| Mankind Pharma Limited | 28.09 Billion INR | 83.099% |
| Sequent Scientific Limited | 549.8 Million INR | -763.62% |
| Laurus Labs Limited | 8 Billion INR | 40.692% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 49.135% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 58.143% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 91.555% |
| Amrutanjan Health Care Limited | 681.59 Million INR | -596.627% |
| Wockhardt Limited | 1.08 Billion INR | -339.647% |
| Bal Pharma Limited | 345.59 Million INR | -1273.928% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 94.621% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -221.034% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -1980.949% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 23.216% |
| Shilpa Medicare Limited | 2.58 Billion INR | -83.47% |
| Valiant Laboratories Limited | 12.73 Million INR | -37172.816% |
| Ajanta Pharma Limited | 12.56 Billion INR | 62.212% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -10412.972% |
| Granules India Limited | 8.6 Billion INR | 44.813% |
| Medicamen Biotech Limited | 245.66 Million INR | -1832.827% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -1003.521% |
| Piramal Enterprises Limited | -3.86 Billion INR | 222.975% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 86.438% |
| NATCO Pharma Limited | 18.79 Billion INR | 74.737% |
| Suven Life Sciences Limited | -992.78 Million INR | 578.272% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 5839.582% |
| Strides Pharma Science Limited | 3.76 Billion INR | -26.125% |
| Indoco Remedies Limited | 2.64 Billion INR | -79.376% |
| Alpa Laboratories Limited | 229.96 Million INR | -1964.778% |
| Lasa Supergenerics Limited | -65.08 Million INR | 7395.919% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 227.247% |